.png?width=150&name=MMS%20logo_without%20Tagline%20(Full%20Color).png "MMS logo_without Tagline (Full Color)")
How does the European Union Clinical Trial Information System (EU-CTIS) Affect Clinical Trial Transparency?
By: Aaron Burr, Ph.D., Senior Medical Writer, Jennica Young, Ph.D., Clinical Trial Transparency Specialist, ...
Clinical Trial Disclosures 101: The Basics You Need to Know
As regulations around clinical trial data disclosure continue to increase in complexity, it can be difficult ...
How to Solve Challenges in Plain Language Summary Writing
By: Michelle Reed, Associate Manager of Regulatory and Medical Writing
How to Train Users on the Clinical Trial Information System (CTIS) Ahead of New Regulations
By: Kasim McLain, Manager of Transparency
Attention Sponsors, Be Prepared to Publish Interim Clinical Study Results
By Karim Ibazatene, Associate Director of Clinical Trials Transparency Right ...
EU Clinical Trials Regulation: The Need for Coordination by Sponsors
Planning, timing, and coordination. These three words may be the magic formula that Sponsors will have to ...
Why You Should Update Your Clinical Trial Disclosure Policy for the EU Clinical Trials Regulation and ICMJE Requirements Now
By Karim Ibazatene, Associate Director, Transparency
Planning for Health Canada’s New Transparency Initiatives for Clinical Data
In March 2019, Health Canada created a new transparency requirement. Health Canada’s Public Release of ...
FREE DOWNLOAD: Lay Summary Whitepaper
This complimentary lay summary whitepaper will explain:
Why Lay Summaries Matter and Their Future
Plain language summaries, commonly known as lay summaries, have become increasingly important for ...